Patents Examined by Frank C. Eisenschenk
  • Patent number: 6184414
    Abstract: Process for producing ammonium-2-hydroxy-4-(methylthio)-butyrate, mixtures containing the same in liquid form and their use. In order to produce ammonium-2-hydroxy-4-methylthio-n-butyrate and mixtures containing the same with a remarkable fluidity and a very low oligomer proportion by a process based on exclusively “liquid” steps, the reaction mixture is treated with a water-immiscible or partially water-miscible inert solvent, until a first organic extract and a first aqueous raffinate are obtained, and the first organic extract is decomposed into a second organic extract and a second aqueous raffinate by treating it with ammonia and phase separation. Re-extraction of MHA as MHAAS is carried out in the second aqueous raffinate, causing salt formation, and MHAAS is isolated from the second aqueous raffinate. This compound is useful as feedstuff supplement and as methionine substitute.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: February 6, 2001
    Assignee: Degussa Aktiengesellschaft
    Inventors: Helmut Suchsland, Heinz Kohl
  • Patent number: 6180768
    Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2i, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: January 30, 2001
    Assignee: Innogenetics N.V.
    Inventors: Geert Maertens, Lieven Stuyver
  • Patent number: 6156567
    Abstract: Recombinant adenoviruses, methods of making them, uses for them, including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector, expression products from them, and uses for the expression products are provided. More particularly, recombinant canine adenoviruses (CAV) and methods of making them, uses for them, expression products from them, and uses for the expression products, including recombinant CAV2 viruses are provided. Additionally, truncated promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes are provided.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: December 5, 2000
    Assignee: Merial
    Inventor: Laurent Fischer
  • Patent number: 6127150
    Abstract: The present invention is directed to a protein purification construct having three tandem, coupled segments composed of a binding protein, an interconnecting linker and a variable fused polypeptide which incorporates the one or more copies of a product peptide. The binding protein is a mammalian or human carbonic anhydrase, or a modified version of the carbonic anhydrase. The protein purification construct may be employed in methods for expression of the product peptide in microbial and higher organism and for ligand immobilized affinity purification of the product peptide.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: October 3, 2000
    Assignee: BioNebraska, Inc.
    Inventors: Thomas R. Coolidge, Fred Wagner, Gino van Heeke, Sheldon M. Schuster, Jay Stout, Dwane E. Wylie
  • Patent number: 6093405
    Abstract: Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when administered to a subject in need thereof to treat homeostatic conditions and disorders associated with an overproduction of cytokines.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: July 25, 2000
    Assignee: Neovacs
    Inventors: Daniel Zagury, Jean-Fran.cedilla.ois Zagury, Bernard Bizzini
  • Patent number: 6090930
    Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: July 18, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
  • Patent number: 6066324
    Abstract: Recombinant papilloma virus-like particles result from the expression of viral structural protein L1 and/or L2 in which one or several sections of the L1 and/or L2 protein are deleted. The ability to form virus-like particles is at least the same as, preferably higher than, that of native reproduction and/or in vitro production processes.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: May 23, 2000
    Assignee: Loyola University of Chicago
    Inventors: Lutz Gissmann, Jian Zhou, Martin Muller, Jeanette Painstil
  • Patent number: 6054567
    Abstract: The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: April 25, 2000
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novavax, Inc.
    Inventors: Suzanne U. Emerson, Robert H. Purcell, Sergei A. Tsarev, Robin A. Robinson
  • Patent number: 6051410
    Abstract: Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: April 18, 2000
    Assignee: Therion Biologics, Corp.
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard, Anna Mahr
  • Patent number: 6042835
    Abstract: Molecular clones of feline leukemia virus isolates that encode (a) a prototype highly infectious, minimally pathogenic virus, (b) a variant genome that is replication-defective and associated with a fatal immunodeficiency in cats similar to AIDS (FAIDS) or (c) a chimeric genome that is replication-competent and induces FAIDS. These molecular clones may be used to generate cell lines producing infectious virus which is useful in the preparation of vaccines or in the generation of viremia or disease challenge systems.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: March 28, 2000
    Assignees: Colorado State University Research Foundation, Harvard University
    Inventors: Edward A. Hoover, James I. Mullins
  • Patent number: 6034059
    Abstract: IGF-1 and a hypocaloric amount of nutrient are used to treat a catabolic state in a patient. The IGF-1 and nutrient can be administered simultaneously, separately or sequentially. The amounts of IGF-1 and hypocaloric amount of nutrient are effective for the treatment of the catabolic state.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: March 7, 2000
    Assignee: Chiron Corporation
    Inventors: Linda Fryklund, Peter Gluckman, Anna Skottner
  • Patent number: 6028118
    Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumoral, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a homogenate of cartilage in an aqueous solution, this homogenate being separated in a solid fraction (SOLID EXTRACT) and a liquid fraction which was further fractionated to obtain a LIQUID EXTRACT having molecules of a molecular weight comprised between 0 to 500 kDa. The composition of the liquid extract has then been investigated by different ways. Further fractionation of this extract led to the preliminary characterization of some of its active components.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: February 22, 2000
    Assignee: Les Laboratoires Aeterna Inc.
    Inventors: Eric Dupont, Paul Brazeau, Christina Juneau, Daniel H. Maes, Kenneth Marenus
  • Patent number: 6017541
    Abstract: Methods are described for the rapid synthesis in satisfactory yield of methyl ecgonine phenylphosphonates as analogues of transition states for the hydrolysis of the benzoyl ester of an ecgonine derivative, namely cocaine, and their linking to carrier proteins, for the purpose of using them as immunogens. The resulting immunogens elicit the formation in experimental animals of antibodies able to promote the hydrolysis of cocaine. Both these catalytic anti-cocaine antibodies and the immunogens themselves are potentially useful for the treatment of individuals seeking to avoid the pharmacological effects of cocaine and in diagnostic applications.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: January 25, 2000
    Inventors: Brian H. Barber, Neal den Hollander, Jiri J. Krepinsky, M. Younus Meah
  • Patent number: 6015695
    Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: Vrije Universiteit Brussel
    Inventors: Cecile Casterman, Raymond Hamers
  • Patent number: 6013484
    Abstract: Described is a new variety of retrovirus designated HIV-3, samples of which are deposited in the European Collection of Animal Cell Cultures (ECACC) under V88060301. Further described are antigens obtained from the virus, particularly proteins p12, p16, p25 and glycoproteins gp41 and gp120 to be used in the diagnosis of ARC or AIDS caused by HIV-3. Immunogenic compositions to be used as vaccines contain an envelope glycoprotein of HIV-3 such as gp41 or gp120.
    Type: Grant
    Filed: July 25, 1997
    Date of Patent: January 11, 2000
    Assignee: Innogenetics N.V.
    Inventors: Robert De Leys, Bart Vanderborght, Eric Saman, Hugo Van Heuverswyn
  • Patent number: 6013532
    Abstract: Microbiological entities, such as cells or microbes, are immobilized in a single-file linear array for optical analysis. Colloidal magnetic particles having a binding agent, such as ligand for attachment with a corresponding receptor, are bound to the entities suspended in a fluid medium. The fluid medium is placed into a vessel having a ferromagnetic capture structure including an elongated linear collection surface with a diameter less than that of the microbiological species of interest. The vessel is placed into a magnetic field for inducing a magnetic gradient in a region along the collection surface of the ferromagnetic capture structure. The magnetically-labeled entities are attracted toward the collection surface and immobilized thereon in a linear array. Microscopic optical and fluorescence observations, and sequential chemical reactions and mechanical manipulations may be performed on the line of immobilized entities.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: January 11, 2000
    Assignee: Immunivest Corporation
    Inventors: Paul A. Liberti, Yuzhou Wang
  • Patent number: 6004798
    Abstract: A retroviral vector particle having a modified retroviral envelope polypeptide. The retroviral envelope polypeptide includes the hypervariable polyproline region, or hinge region, and the hypervariable polyproline region, or hinge region is modified to include a targeting polypeptide including a binding region which binds to a ligand. Such a retroviral vector may be "targeted" to various cells for delivery of genetic material to such cells.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: December 21, 1999
    Assignee: University of Southern California
    Inventors: W. French Anderson, Bonnie Weimin Wu
  • Patent number: 6001555
    Abstract: The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: December 14, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Louis E. Henderson, Larry O. Arthur, William G. Rice, Alan R. Rein
  • Patent number: 5997934
    Abstract: A process for the manufacture of cooked cereals or dry pet food which comprises preparing a mixture of water and a dry premix mainly comprising cereal flour or semolina, cooking the mixture and extruding it by pressing it through an extrusion die with the aid of a gear pump.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: December 7, 1999
    Assignee: Nestec S.A.
    Inventors: Osvaldo Geromini, Ernst Heck, Jean Noel Huet, Thierry Martin, Werner Pfaller
  • Patent number: 5993865
    Abstract: The present invention concerns a beverage containing proteins and/or peptides and is characterized in that it contains Cereal-LT and/or homologues as herein defined and/or a modified Cereal-LTP fraction obtainable from the Cereal-LTP and/or homologues by heating, boiling and/or mashing the Cereal-LTP and/or homologues in water at a pH between 3 and 7. The invention also concerns a method for preparing it and a use of a foam-forming additive.
    Type: Grant
    Filed: June 26, 1996
    Date of Patent: November 30, 1999
    Assignee: Carlsberg A/S
    Inventors: Lene M.o slashed.lskov Bech, Steen Bech S.o slashed.rensen, Pia Vaag, Marianne Muldbjerg, Thorkild Beenfeldt, Robert Leah, Klaus Breddam